FDA approves gene tektronix antibody conjugate drug Polivy for treatment of incurable diffuse large B-cell lymphoma in adult patients

today, the United StatesThe FDA(http://announced the accelerated approval of gene tektronix's antibody conjugatedrug(http://Polatuzumab vedotin-piiq, in combination with benzoisande and rituximab, to treat adult patients with incurable diffuse large B-cell lymphomaAbout Polivy
Polivy is an antibody-linked drug (ADC) that targets cd79b protein serotto on the surface of B cells at one end and chemotherapy drugs on the otherIt is envisaged that when it specifically binds to and enters B cells in the body, it releases chemotherapy drugs to kill the cells, thus controlling the cancerPolivy's efficacy was validated in a 1b/2 clinicaltrial(http://The trial assessed 80 patients with recurrent or refractory DLBCL, who were randomly divided into two groups, one receiving standard benzoisandorandias and rituximab, and the other using Polivyresults showed that in the standard treatment group, the patient's total remission rate was 18%In the Polivy treatment group, the figure was 40 percent in addition, 64 percent of patients who had partial or complete remission in the Polivy treatment group had more than half of the duration of the remission, and nearly half (48 percent) of those who had been in the Polivy treatment group for more than half of the year It is also the only clinical trial in a randomized clinical trial that shows higher remission rates than this standard therapy, Genetek said in its press release 　　Based on these excellent results, the FDA today accelerated the approval of Polivy in conjunction with standard therapies to treat patients with these incurable lymphomas before that, Polivy was awarded the FDA's ground-breaking therapeutic designation, priority review qualification, and orphan drug eligibility